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ABSTRACT 
 
LIPOPROTEIN SUBCLASS MEASUREMENTS BY AN UPDATED NUCLEAR 
MAGNETIC RESONANCE SPECTROSCOPY METHOD IN THE PREDICTION OF 
CORONARY ARTERY DISEASE IN TYPE 1 DIABETES 
 
 
 
By 
Qing Xu 
August 2014 
 
Thesis supervised by Dr. John Kern and Dr. Tina Costacou. 
 
BACKGROUND: Although individuals with type 1 diabetes generally exhibit a normal 
lipid profile compared to the general population, they are reported to have up to a tenfold 
increased coronary artery disease (CAD) risk. It was thus thought that the study of 
lipoprotein subfractions measured by nuclear magnetic resonance spectroscopy (NMR) 
could potentially better discriminate those with type 1 diabetes at high CAD risk. Over 
the years, however, the method used to classify lipoprotein subfractions has changed.  
OBJECTIVE: Our aim was therefore to compare the predictive ability of two distinct 
methods (version 1 and version 3) of classifying HDL lipoprotein subfractions by NMR 
in terms of CAD incidence in a large cohort of individuals with type 1 diabetes. 
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METHODS: We used data from participants from the Pittsburgh Epidemiology of 
Diabetes Complications study (EDC), a prospective investigation of individuals with 
childhood onset type 1 diabetes, who were free of CAD at baseline (260 men, 262 
women; mean age 27.7 and diabetes duration 19.5 years). CAD was defined as angina, 
ischemic electrocardiogram changes, confirmed myocardial infarction, angiographic 
stenosis ≥50%, revascularization, or CAD death. Lipoprotein subfractions by NMR were 
measured at the first available stored serum sample using either version 1 or version 3. 
Separate Cox proportional hazards models were constructed to evaluate the predictive 
ability of the two NMR versions. 
RESULTS: Results from multivariable Cox models were essentially identical for the two 
NMR versions:  large HDL particle concentration measured by either NMR version 1 or 
version 3 was inversely related to the incidence of CAD in this population.  Furthermore, 
when HDL and non-HDL cholesterol (measured enzymatically) were allowed for in the 
same model as the HDL subfractions by NMR, both non-HDL cholesterol and large HDL 
particle concentration by NMR were selected as independent predictors of developing 
CAD, regardless of the NMR version used. 
CONCLUSION: We were not able to identify differences in the predictive ability of 
HDL lipoprotein subfractions in relation to CAD incidence between the two different 
versions of obtaining NMR lipoprotein subfractions, suggesting that study findings are 
comparable with either version. Our results further suggest that large HDL particle 
concentration by NMR contributes to the prediction of CAD incidence in addition to the 
current standard of enzymatically measured lipoprotein concentrations. 
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Introduction  
The role of low density lipoprotein (LDL) cholesterol as a major risk factor for 
the development of cardiovascular disease is widely accepted.  Indeed, major health 
organizations, such as the American Diabetes Association and the American Heart 
Association, recommend increased efforts to keep LDL concentrations within target as a 
means of subsequently reducing the incidence of atherosclerosis, especially among 
individuals with diabetes1.   
However, the role of high density lipoprotein (HDL) cholesterol in the 
development of cardiovascular disease is not as clear as that of LDL. Although earlier 
studies have suggested an inverse association between HDL cholesterol concentrations 
and CAD incidence2, more recently published data have also shown direct relationships. 
It has thus been proposed that the study of subfractions of HDL in relation to CAD 
incidence may clarify some of these discrepancies. 
In the early 2000s, lipoprotein subfractions by nuclear magnetic resonance 
spectroscopy (NMR) were measured as part of a nested, within the Epidemiology of 
Diabetes Complications study (EDC) cohort, coronary artery disease (CAD) case-control 
study in 142 study participants2, 3, 4, 5, 6, 7. Findings in this paper showed that increased 
large HDL particle concentration by NMR was related to a decreased CAD risk while 
medium HDL particle concentration by NMR was positively related to CAD incidence.  
The methodology of assessing lipoprotein subfractions by NMR has since been altered, 
however. Thus, during 2010, lipoprotein subfractions by nuclear magnetic resonance 
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spectroscopy (NMR) were measured again in the EDC study, using an updated NMR 
methodology at the first available stored serum sample of EDC study participants. 
Thus, the aim of this paper was to compare assay results obtained using the earlier 
(version 1) NMR methodology with those using the most recent (version 3) NMR 
methodology, and to differentiate individuals who developed coronary artery disease 
from those who did not, based on the individuals’ demographic and clinical 
characteristics as well as their NMR findings.  
 3 
 
Methods  
The Pittsburgh Epidemiology of Diabetes Complications (EDC) study is a 
historical cohort study based on incident childhood onset (<17 years) type 1 diabetes 
(T1DM) cases that were diagnosed, or seen within one year of diagnosis, at Children’s 
Hospital of Pittsburgh between 1950 and 1980. A description of the EDC study has been 
published previously8.  
This population, previously shown to be representative of the T1DM population 
of Allegheny County, Pennsylvania, was first examined for the EDC study between 1986 
and 1988. Six hundred and fifty eight individuals were willing and eligible to participate 
in the study and have been followed by survey biennially ever since. Full biennial 
examinations were conducted at the 10, 18 and (currently) 25 year assessment. At each 
biennial follow-up, participants were asked to complete questionnaires concerning 
demographic, health care, self-care, medications, and medical history information. Only 3 
participants have failed to provide any follow-up data, while another 35 have asked not to 
be contacted at various time points. At the clinical visits, complications were assessed by 
physical examination, testing for peripheral and autonomic neuropathy, collecting timed 
urine specimens, and conducting electrocardiograms and fundus photographs. Two 
assessments, about 4-6 years apart (1996-1998 and 2002-2004), have been made of 
coronary artery calcification (CAC).  Additionally, blood is drawn at each clinical visit 
for assessment of HbA1c, lipids, complete blood count and many other risk factors and 
biomarkers.  In all, over 150 risk "markers" have been assayed at various time points. 
Details of methods measuring some of these variables were recorded in previous 
publications.  As previously described, blood pressure was obtained with a random zero 
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sphygmomanometer, after a 5-minute rest, and hypertension was defined as ≥140/90 
mmHg or use of antihypertensive medication. Stable glycosylated hemoglobin (HbA1) 
was measured by ion exchange chromatography (Isolab, Akron, OH) and subsequently 
by automated high-performance liquid chromatography (Diamat; BioRad, Herchules, 
CA). The two assays were highly correlated (r=0.95). 
Cholesterol in the High-density lipoprotein fraction and HDL3 cholesterol 
subfraction was measured enzymatically after precipitation with heparin/manganese and 
dextran sulfate, respectively. Cholesterol and triglycerides were measured enzymatically.  
Non-HDL cholesterol was calculated as total minus HDL cholesterol. LDL cholesterol 
was calculated using the Friedewald equation.  
White blood cell count was measured by the use of a counter S-plus IV and 
fibrinogen with a biuret colorimetric procedure and a clotting method. Urinary albumin 
was measured by immunonephelometry. Creatinine was obtained by an Ectachem 400 
Analyzer (Eastman Kodak Co., Rochester, NY). A person who has smoked 100+ lifetime 
cigarettes was defined as an ever-smoker.  
The earliest available frozen EDTA plasma sample was chosen and shipped on 
dry ice to Liposcience, Inc. (Raleigh, NC) for NMR lipoprotein particle analysis by the 
earliest (version 1) as well as the most recent (version 3) version of this technique. When 
the available sample was inadequate to obtain measurements by both NMR versions, if 
available, a sample from the next available examination cycle was used for the earliest 
version of NMR; this practice was necessary for only seven individuals. Particle 
concentrations of lipoproteins of different sizes were calculated from the measured 
amplitudes of their spectroscopically distinct lipid-methyl group15.  Weighted-average 
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lipoprotein particle sizes were derived from the sum of the diameter of each subclass 
multiplied by its relative mass percentage based on the amplitude of its methyl NMR 
signal. 
Coronary artery disease was determined by EDC study physician-diagnosed 
angina, myocardial infarction confirmed by Q-waves on electrocardiogram (Minnesota 
codes 1.1 or 1.2) or hospital records, angiographic stenosis ≥50%, coronary artery bypass 
surgery, angioplasty, ischemic electrocardiogram changes (Minnesota codes 1.3, 4.1-4.3, 
5.1-5.3, 7.1), or death from CAD. 
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Statistical analysis 
Prior to conducting statistical testing, simple descriptive statistics were created, 
including the Shapiro-Wilk test for all continuous variables to evaluate normality and 
frequency distributions for categorical variables. Simple univariate associations between 
each risk factor and the subsequent incidence of CAD were determined using parametric 
or non-parametric tests, as appropriate. Thus, for normally distributed continuous 
variables according to the results of the Shapiro-Wilk test, the Student’s t-test was used to 
determine univariate associations with subsequent incidence of CAD and the means and 
standard deviations of the mean (SD) were recorded. For non-normally distributed 
continuous variables, the non-parametric Wilcoxon 2-sample test was used to evaluate 
the univariate association with CAD incidence and the median, first and the third 
quintiles were recorded. For categorical variables, either the χ2 or Fisher’s exact test was 
conducted, as appropriate. Similar statistical analyses were also conducted on participants 
by gender and subsequent CAD status. 
Correlation coefficients, Pearson and Spearman for normally and non-normally 
distributed variables, respectively, were used to assess the presence of an association 
among continuous variables.  
Four separate Cox proportional hazards models with backward elimination were 
constructed for each NMR version to evaluate the predictive ability of the two NMR 
versions for CAD incidence. The first model allowed for traditional CAD risk factors and 
univariately significant variables, in addition to enzymatically measured lipid 
concentrations. The second model allowed for traditional CAD risk factors and 
univariately significant variables (as Model 1), but replaced enzymatically measured lipid 
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concentrations with HDL subfractions measured by NMR. The third model was 
constructed as Model 1 but replaced enzymatically measured lipid concentrations with 
HDL size as measured by NMR. Finally, the fourth model considered both enzymatic and 
HDL subfractions by NMR simultaneously. Survival time was calculated as time in years 
from study entry to either an incident event or censorship during the 25-year follow-up. 
Non-normally distributed continuous variables were logarithmically transformed prior to 
entry in the Cox models. The proportional hazards assumption was evaluated for all 
variables before entry into multivariable models and time dependent covariates were 
created for variables HbA1c, enzymatically measured Non-HDL cholesterol, Albumin 
excretion rate, where the assumption was not satisfied.  
Statistical Analysis Software (SAS) version 9.3 (SAS Institute, Cary, NC) was 
used. 
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Results 
During 20 years of follow-up, 26.6% of the 522 participants with childhood onset 
type 1 diabetes and free of CAD at baseline developed CAD.  Incidence was similar 
between men and women, with 28.8% of 260 men and 24.4% of 262 women developing 
CAD.   
Participant characteristics at baseline by subsequent CAD status are shown in 
Table 1.  CAD incident cases were more likely to be older, with a longer duration of 
diabetes, to have ever smoked, have hypertension, larger waist to hip ratio, higher body 
mass index, pulse rate, markers of inflammation, albumin excretion rate and serum 
creatinine, and lower insulin dose per body weight, estimated glucose disposal rate, and 
glomerular filtration rate by any of the three formulae used (i.e. CKD-Epi, MDRD and 
Cockcroft-Gault). Other traditional risk factors, such as gender and HbA1c, were not 
significant univariate predictors of subsequent CAD in this type 1 diabetes cohort. 
As expected, higher enzymatically measured total cholesterol, LDL cholesterol, 
Non-HDL cholesterol, and lower HDL cholesterol were associated with subsequent CAD 
in this type 1 diabetes cohort. Lower HDL3 subfraction was also associated with CAD 
incidence, while a significant association was not observed for HDL2.  
Lipoprotein subclasses by NMR (version 1 and version 3), expressed in particle 
concentration units, and average lipoprotein particle size by CAD incidence are also 
shown in Table 1. Similar associations with incident CAD were noted between the two 
versions of NMR-measured lipoprotein subclasses. For both NMR versions, among the 
HDL subclasses, large HDL particle concentration, small HDL particle concentration and 
mean HDL particle size differed between the CAD cases and Non-CAD cases, while total 
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HDL particle concentration and medium HDL particle concentration did not differ 
between the two groups. Lower levels of large HDL particle concentration, higher level 
of small HDL particle concentration and smaller mean HDL particle size were significant 
predictors of subsequent CAD incident. All three VLDL subclasses as well as total 
VLDL were significantly higher in CAD cases compared to Non-CAD cases while mean 
VLDL size did not differ between the two groups, regardless of the version of NMR. 
Among the LDL subclasses, small LDL and medium LDL levels as well as total LDL 
were higher in the CAD group than in Non-CAD cases for both NMR versions. However, 
mean LDL particle size was significantly smaller in the CAD group compared to the 
Non-CAD group for version 3 NMR (p=0.001), while there was only a borderline 
difference in mean LDL particle size between the two groups using version 1 NMR 
(p=0.08). Furthermore, higher NMR calculated triglycerides, total cholesterol, VLDL and 
chylomicron triglyceride, and total LDL cholesterol and lower total HDL cholesterol 
were seen in subsequent CAD incident cases than in those who did not have a CAD 
event, regardless of the version of NMR used. 
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Table 1. Characteristics by CAD status 
Participant characteristics CAD NO CAD P-value 
 
(n=139) (n=383) 
 
NMR version 1 
   
Total HDL particle concentration 
(nmol/l) 
30.14 (27.59-33.31) 30.06 (27.16-33.11) 0.4479 
Large HDL particle concentration 
(nmol/l) 
4.89 (3.18-6.85) 5.78 (4.28-8.26) 0.0001 
Medium HDL particle concentration 
(nmol/l) 
4.26 (2.51-7.18) 4.45 (2.3-6.93) 0.6571 
Small HDL particle concentration 
(nmol/l)) 
20.3 (5.54) 18.9 (5.13) 0.0077 
Mean HDL particle size (nm) 9.02 (8.84-9.38) 9.16 (8.9-9.54) 0.0064 
    
Total VLDL particle concentration 
(nmol/l) 
54.86 (42.72-68.72) 42.81 (32.78-56.05) <.0001 
Large VLDL particle concentration 
(nmol/l) 
0.34 (0.07-1.38) 0.16 (0.05-0.62) 0.0006 
Medium VLDL particle concentration 
(nmol/l) 
21.49 (13.8-30.52) 15.83 (10.84-23.63) <.0001 
Small VLDL particle concentration 
(nmol/l) 
29.59 (20.78-41.56) 25.51 (17.17-33.21) 0.0012 
Mean VLDL particle size (nm) 41.31 (38.32-44.71) 40.65 (38.11-43.93) 0.3025 
  
   
Total LDL particle concentration 
(nmol/l) 
1089.23 (871.88-1302.9) 913.77 (739.56-1118.64) <.0001 
Large LDL particle concentration 
(nmol/l) 
398.22 (213.88-533.37) 386.65 (233.26-546.22) 0.8341 
Medium LDL particle concentration 
(nmol/l) 
156.2 (71.06-313.16) 100.17 (41.27-195.17) 0.0001 
Small LDL particle concentration 
(nmol/l) 
387.27 (243.93-623.4) 344.62 (154.55-565.2) 0.0319 
Mean LDL particle size (nm) 20.73 (20.34-21.25) 20.87 (20.4-21.31) 0.0792 
  
   
IDL particle concentration (nmol/l) 42.85 (14.92-74.84) 27.01 (10.71-51.23) 0.0016 
    
NMR calculated triglycerides (mg/dL) 78.36 (64.82-104.18) 63.02 (53.25-80.77) <.0001 
NMR calculated total cholesterol 
(mg/dL) 
156.95 (141.09-176.46) 143.42 (124.82-164.69) <.0001 
NMR calculated VLDL and chyl. Trigl. 
(mg/dL) 
48.24 (35.74-71.46) 35.09 (26.61-51.85) <.0001 
NMR calculated total LDL cholesterol 
(mg/dL) 
95.8 (81.21-115) 82.88 (69.3-99.39) <.0001 
NMR calculated total HDL cholesterol 
(mg/dL) 
44.83 (36.86-51.43) 46.77 (40.32-54.3) 0.0271 
 
Medium (H3) HDL (mg/dL) 6.08 (3.58-10.24) 6.34 (3.28-9.88) 0.6571 
Large (H4+H5) HDL (mg/dL) 18.22 (11.07-27.08) 20.4 (14.61-31.57) 0.001 
Small (H1+H2) HDL (mg/dL)) 18.46 (4.71) 17.26 (4.48) 0.0083 
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Large (V5+V6) VLDL (mg/dL) 4.02 (1.94-12.5) 2.57 (1.09-6.53) 0.0011 
Medium (V3+V4) VLDL (mg/dL) 27.52 (18.77-40.13) 20.8 (14.41-30.03) <.0001 
Small (V1+V2) VLDL (mg/dL) 13.68 (9.4-18.01) 10.96 (7.61-14.65) <.0001 
  
   
Large LDL (mg/dL) 44.98 (24.16-60.24) 43.67 (26.34-61.69) 0.8346 
Medium LDL (mg/dL) 13.47 (6.13-27) 8.64 (3.56-16.83) 0.0001 
Small LDL (mg/dL) 24.97 (15.73-40.2) 22.22 (9.97-36.45) 0.0318 
    
IDL (mg/dL) 4.95 (1.72-8.65) 3.12 (1.24-5.92) 0.0016 
    
NMR version 3 
   
Total HDL concentration (nmol/l) 31.40 (27.80-35.00) 31.20 (28.20-34.45) 0.9891 
Large HDL concentration (nmol/l) 4.70 (3.30-6.30) 5.20 (4.00-6.85) 0.005 
Medium HDL concentration (nmol/l) 10.20 (7.00-13.20) 10.20 (7.45-13.70) 0.3876 
Small HDL (nmol/l) 15.84 (4.75) 14.82 (4.55) 0.0266 
Mean HDL particle size (nm) 9.40 (9.00-9.70) 9.50 (9.20-9.80) 0.0072 
    
Total VLDL concentration (nmol/l) 44.20 (32.70-65.60) 35.15 (26.65-46.7) <.0001 
Large VLDL concentration (nmol/l) 2.00 (1.30-3.10) 1.40 (0.80-2.30) <.0001 
Medium VLDL concentration (nmol/l) 9.10 (5.10-15.10) 7.40 (4.45-11.15) 0.0031 
Small VLDL concentration (nmol/l) 33.80 (24.30-47.80) 26.65 (18.3-35.85) <.0001 
Mean VLDL particle size (nm) 45.95 (43.50-48.70) 45.90 (42.95-49.10) 0.9121 
    
Total LDL concentration (nmol/l) 949.0 (792.0-1180.0) 783.5 (645.0-972.5) <.0001 
Large LDL concentration (nmol/l) 257.0 (131.0-411.0) 261.0 (135.5-418.5) 0.4384 
Small LDL concentration (nmol/l) 521.0 (82.0-705.0) 342.5 (54.0-503.5) <.0001 
Mean LDL particle size (nm) 20.80 (20.30-21.30) 21.10 (20.60-21.50) 0.0013 
    
IDL concentration (nmol/l) 226.0 (165.0-331.0) 200.0 (125.5-286.5) 0.0018 
    
NMR calculated VLDL & chyl. trigl. 
(mg/dL) 
57.20 (41.30-78.60) 44.20 (34.25-60.70) <.0001 
NMR calculated total triglycerides 
(mg/dL) 
93.00 (78.00-119.00) 78.00 (66.50-95.00) <.0001 
NMR calculated total HDL cholest. 
(mg/dL) 
45.00 (38.00-51.00) 47.00 (42.00-52.00) 0.0134 
  
   
Non-NMR variables 
   
Glomerular filtration rate CDK-Epi   99.35 (74.49-117.59) 111.43 (91.5-128.31) <.0001 
Glomerular filtration rate MDRD   85.4 (64.94-108.84) 97.43 (79.55-124.31) <.0001 
Glomerular filtration rate Cockcroft-
Gault 
103.72 (80.75-131.05) 116.27 (94.9-143.14) 0.0009 
  
   
Total cholesterol (enzymatic) 197 (177-226) 174 (156-201) <.0001 
HDL cholesterol (enzymatic) 50.4 (42.1-59.8) 53 (46.5-61.4) 0.0104 
LDL cholesterol (enzymatic) 123 (106.2-147) 102.6 (88.8-125.3) <.0001 
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Non-HDL cholesterol (enzymatic) 146.1 (124.5-173.1) 118.65 (101.15-144.45) <.0001 
  
   
HDL3 by old Heinz lab method 37.8 (32.4-43.8) 39.7 (35.6-43.7) 0.0071 
HDL2 by old Heinz lab method 12.2 (8.8-19) 13.3 (8.5-19.6) 0.3423 
  
   
Albumin excretion rate 27.85 (8.7-380.52) 10.96 (6.49-35.65) <.0001 
Body mass index 23.86 (21.93-26.46) 23.11 (21.38-25.24) 0.0121 
Diastolic blood pressure 74 (67-83) 70 (65-76) <.0001 
Systolic blood pressure 114 (106-127) 108 (102-115) <.0001 
Fibrinogen 300 (240-370) 270 (225-325) 0.0022 
White blood cell count 6.6 (5.7-8.1) 6.1 (5.2-7.3) 0.0003 
Estimated glucose disposal rate 7.29 (5.85-8.48) 8.4 (7.28-9.32) <.0001 
HbA1c 8.73 (7.86-9.85) 8.52 (7.69-9.77) 0.0702 
Insulin dose per body weight 0.7 (0.58-0.85) 0.79 (0.63-0.94) 0.0033 
Serum creatinine 0.9 (0.7-1.1) 0.8 (0.7-1) 0.0016 
Waist to hip ratio 0.84 (0.79-0.9) 0.82 (0.76-0.86) 0.0008 
Age 32.49 (28.28-38.57) 24.94 (20.74-30.66) <.0001 
Duration of diabetes 25.04 (18.89-30.09) 16.77 (11.79-21.96) <.0001 
PULSE 80 (72-84) 76 (70-82) 0.0262 
Chylos (mg/dL) 0.33 (0-0.74) 0.46 (0-1.04) 0.0262 
Having ever smoked (%, n) 48.6 (67) 31.0 (117) X2: 0.0002 
Hypertension (%, n) 24.6 (34) 8.9 (34) X2<0.0001 
Sex (%, n) 
   
  Men 54.0 (75) 48.3 (185) X2: 0.2535 
  Women 46.0 (64) 51.7 (198) 
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Given previously observed differences in the relationship between HDL 
cholesterol (and subfractions) and CAD in men and women10, univariate analyses were 
also repeated stratifying by gender. Generally, similar associations were observed in men 
and women for traditional risk factors, with the exception of body mass index, diastolic 
blood pressure, albumin excretion rate and fibrinogen, which were significant univariate 
predictors of CAD only in men. For the enzymatically measured lipid concentrations, 
associations in men remained consistent with those observed in the overall cohort, while 
no significant differences in HDL cholesterol concentrations by CAD incidence were 
noted in women. 
 The relationship between lipoprotein subclasses by NMR and incident CAD 
differed by NMR version as well as by gender and are presented in Table 2. Among the 
HDL subclasses, with version 1 NMR, both large HDL particle concentration and mean 
HDL particle size were lower in subsequent CAD cases in men, while in women, only 
large HDL differed significantly, being lower in subsequent CAD cases. With version 3 
NMR, only large HDL particle concentration remained different by CAD in men, while 
other HDL subclasses, including total, medium and small HDL as well as mean HDL 
particle size, lost the significance by CAD status. In women, none of the NMR version 3 
HDL subclasses and mean HDL particle size differed by incident CAD status. 
 For VLDL subclasses, in men, the relationships with incident CAD were in the 
same direction as in overall cohort, and thus, all three subclasses as well as total VLDL 
particle concentration were elevated in incident CAD cases compared to non-cases, for 
both version 1 NMR and version 3 NMR. However, in women, when using version 1 
NMR, only total VLDL and medium VLDL were significantly elevated in incident CAD 
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cases. When using version 3 NMR, significant differences by CAD status remained for 
total VLDL, large VLDL and medium VLDL, while a borderline significant difference 
was also observed for small VLDL (p=0.05). 
 Among LDL subclasses, when using version 1 NMR, in men, total LDL and 
medium LDL particle concentrations were higher by incident CAD, while in women, 
only total LDL particle concentration was higher in CAD cases. When using version 3 
NMR, the relationship remained generally the same as in the overall cohort, thus, total 
LDL and small LDL particle concentrations were elevated in incident CAD cases 
compared to non-cases regardless of gender. Mean LDL size was smaller in CAD cases 
in men, while it did not differ by CAD status in women.  
 For IDL, both in the overall cohort and by gender, particle concentrations were 
higher in incident CAD cases compared to non-cases. 
 When using version 1 NMR, NMR calculated triglycerides, total cholesterol, 
VLDL and chylomicron triglyceride, and total LDL cholesterol were higher in CAD 
cases, while there was no difference by CAD status in total HDL cholesterol, in both men 
and women. When using version 3 NMR, in women there was no difference in NMR 
calculated total HDL cholesterol, whereas in men, NMR calculated total HDL cholesterol 
was lower in CAD cases compared to non-cases. The other two NMR calculated 
measurements, total triglycerides as well as VLDL and chylomicron triglyceride were all 
significantly higher in CAD cases in both men and women.  
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Table 2 Characteristics by Gender and CAD 
Version 1 Men Women 
 
CAD 
(n=75) 
NO CAD 
(n=185) 
p-
value 
CAD 
(n=64) 
NO CAD 
(n=198) 
p-
value 
Total HDL particle 
concentration (nmol/l) 
29.98 (27.3-33.5) 30.2 (27.17-33.01) 0.6666 30.73 (28.09-33.17) 29.92 (27.13-33.43) 0.5071 
Large HDL particle 
concentration (nmol/l) 
3.97 (2.63-5.59) 4.92 (3.38-6.83) 0.0024 6.37 (3.92-8.32) 7.08 (5.04-9.29) 0.0416 
Medium HDL particle 
concentration (nmol/l) 
4.02 (2.78-6.73) 4.48 (2.53-6.77) 0.9708 4.58 (2.5-7.83) 4.38 (1.76-7.16) 0.6005 
Small HDL particle 
concentration (nmol/l)) 
21.33 (17.72-24.98) 20.17 (16.91-22.83) 0.0953 19.4 (15.46-22.48) 17.86 (14.6-20.85) 0.1114 
Mean HDL particle size (nm) 8.89 (8.78-9.07) 8.99 (8.81-9.3) 0.0410 9.24 (8.96-9.58) 9.35 (9.04-9.71) 0.1620 
  
  
  
   
Total VLDL particle 
concentration (nmol/l) 
55.28 (45.98-73.37) 43.74 (34.37-56.05) <.0001 53.73 (37.18-66.66) 42.17 (30.26-56.01) 0.0059 
Large VLDL particle 
concentration (nmol/l) 
0.53 (0.22-1.71) 0.21 (0.06-0.71) 0.0028 0.28 (0.05-0.98) 0.11 (0.03-0.49) 0.0559 
Medium VLDL particle 
concentration (nmol/l) 
23.49 (14.07-31.22) 16.4 (11.29-24.33) 0.0010 19.97 (13.3-29.08) 14.99 (10.44-22.95) 0.0113 
Small VLDL particle 
concentration (nmol/l) 
32.21 (24.3-42.23) 25.57 (17.66-32.48) <.0001 26.26 (15.09-39.76) 25.32 (16.19-34.86) 0.6066 
Mean VLDL particle size 
(nm) 
41.4 (38.32-45.18) 41.23 (38.61-45.26) 0.9230 41.31 (38.28-44.15) 39.83 (37.83-43.35) 0.1552 
  
      
Total LDL particle 
concentration (nmol/l) 
1099.63 (927.63-
1346.47) 
923.42 (728.7-
1131.81) 
<.0001 
1083.58 (838.44-
1237.51) 
904.91 (743.24-1106) 0.0015 
Large LDL particle 
concentration (nmol/l) 
325.43 (198.44-482.16) 320.28 (199.36-480.68) 0.7248 479.05 (245.2-652.16) 433.28 (258.61-597.01) 0.6019 
Medium LDL particle 
concentration (nmol/l) 
182.44 (86.88-355.49) 100.17 (39.72-195.17) <.0001 109.47 (47.12-257.5) 100.17 (42.94-195.38) 0.3142 
Small LDL particle 
concentration (nmol/l) 
466.42 (301.52-694.84) 402.19 (233.94-591.38) 0.0870 351.15 (141.31-554.24) 265.08 (99.95-523.62) 0.2400 
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Version 1 Men Women 
 
CAD 
(n=75) 
NO CAD 
(n=185) 
p-
value 
CAD 
(n=64) 
NO CAD 
(n=198) 
p-
value 
Mean LDL particle size (nm) 20.56 (20.24-20.98) 20.71 (20.3-21.17) 0.1847 20.99 (20.42-21.39) 21.07 (20.58-21.47) 0.3996 
       
IDL particle concentration 
(nmol/l) 
38.7 (16.03-68.46) 27.26 (10.65-49.36) 0.0432 46.8 (12.62-88.24) 26.8 (10.81-52.74) 0.0154 
       
NMR calculated triglycerides 
(mg/dL) 
80.37 (66.06-112.41) 65.06 (53.45-81.64) <.0001 75.18 (63.13-93.97) 62.07 (52.89-80.61) <.0001 
NMR calculated total 
cholesterol (mg/dL) 
151.66 (136.88-172.19) 137.7 (120.28-159.41) <.0001 162.34 (145.88-181.77) 149.01 (128.9-169.57) 0.0045 
NMR calculated VLDL and 
chyl. Trigl. (mg/dL) 
52.1 (37.2-77.91) 37.06 (28.3-51.75) <.0001 42.77 (33.81-59.46) 33.65 (24.95-52.12) 0.0007 
NMR calculated total LDL 
cholesterol (mg/dL) 
96.09 (81.21-115.7) 80.87 (68.91-98.15) <.0001 95.52 (80.97-115) 85.74 (70.55-100.94) 0.0011 
NMR calculated total HDL 
cholesterol (mg/dL) 
41.45 (35.21-48.05) 43.91 (37.32-49.61) 0.0719 49.68 (40.74-58.4) 50.47 (43.87-58.79) 0.4605 
  
      
Total cholesterol (enzymatic) 203 (177-230) 168 (153-195) <.0001 192 (176-225) 178.5 (162-206) 0.0016 
HDL cholesterol (enzymatic) 46.5 (40.2-56.4) 49.4 (44-56.5) 0.0181 56.9 (47.5-63.8) 56.45 (50.2-66.8) 0.4503 
LDL cholesterol (enzymatic) 125.7 (110.3-150.85) 102.6 (86.4-126.4) <.0001 118 (102.9-140.5) 102.5 (89.7-123.4) 0.0023 
Non-HDL cholesterol 
(enzymatic) 
149 (131.5-182.9) 117.3 (101.3-145.9) <.0001 138.5 (121.7-165.8) 119.6 (101.1-142.6) 0.0005 
  
  
  
   
Glomerular filtration CDK-Epi 96.64 (69.51-116.89) 111.62 (93.57-127.37) <.0001 100.76 (79.14-118.71) 111.23 (88.67-128.54) 0.0091 
Glomerular filtration MDRD 84.72 (61.98-108.03) 100.73 (82.35-125.74) <.0001 85.79 (68.83-110.95) 96.5 (76.1-123.69) 0.0545 
Glomerular filtration Cockcroft-
Gault 
110.78 (78.16-138.45) 
119.32 (102.29-
143.91) 
0.0121 97.31 (82.44-123.96) 112.82 (87.64-141.92) 0.0323 
Albumin excretion rate 53.66 (9.94-592.08) 11.26 (6.83-36.3) <.0001 19.8 (7.73-235.28) 10.67 (6.22-33.24) 0.0514 
Body mass index 24.56 (22.86-26.46) 23.25 (21.37-25.24) 0.0029 22.86 (20.88-26.63) 22.82 (21.38-25.29) 0.6818 
Diastolic blood pressure 79 (73-85) 73 (66.5-79) <.0001 68 (62-76) 68 (64-73) 0.6377 
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Version 1 Men Women 
 
CAD 
(n=75) 
NO CAD 
(n=185) 
p-
value 
CAD 
(n=64) 
NO CAD 
(n=198) 
p-
value 
Systolic blood pressure 121 (110-135) 111 (105-117) <.0001 111 (100-123) 106 (99-113) 0.0099 
Fibrinogen 300 (220-370) 250 (205-300) 0.0013 300 (250-375) 280 (240-340) 0.2318 
White blood cell count 6.4 (5.5-7.7) 5.8 (5.1-7) 0.0136 6.9 (5.8-8.8) 6.2 (5.3-7.6) 0.0049 
Estimated glucose disposal 
rate 
7.03 (5.21-7.66) 7.91 (6.64-8.7) <.0001 8.13 (6.69-9.28) 9.05 (7.79-9.84) 0.0007 
HbA1c 8.77 (7.94-9.85) 8.52 (7.69-9.77) 0.1712 8.69 (7.69-10.02) 8.52 (7.69-9.64) 0.2547 
Insulin dose per body weight 0.72 (0.6-0.86) 0.81 (0.66-0.94) 0.0260 0.68 (0.54-0.85) 0.77 (0.59-0.93) 0.0332 
Serum creatinine 1 (0.9-1.3) 0.9 (0.8-1.1) 0.0010 0.8 (0.6-0.9) 0.7 (0.6-0.9) 0.3502 
Waist to hip ratio 0.88 (0.84-0.92) 0.86 (0.83-0.89) 0.0017 0.79 (0.74-0.82) 0.76 (0.73-0.8) 0.0411 
Age 31.69 (26.44-37.56) 24.63 (20.73-29.8) <.0001 33.43 (28.47-39.21) 25.24 (20.76-31.06) <.0001 
Duration of diabetes 24.9 (18.22-30.00) 16.64 (11.42-21.55) <.0001 25.37 (19.78-31.05) 16.93 (12.37-21.96) <.0001 
PULSE 80 (72-84) 76 (68-81) 0.0485 80 (70-88) 78 (70-84) 0.1776 
Chylos (mg/dL) 0.31 (0.00-0.69) 0.45 (0.00-1.04) 0.0967 0.33 (0.00-0.82) 0.46 (0.00-1.04) 0.1378 
 
 
Version 3 Men Women 
 
CAD 
(n=75) 
NO CAD 
(n=185) 
p-value 
CAD 
(n=64) 
NO CAD 
(n=198) 
p-value 
Total HDL particle 
concentration (nmol/l) 
30.2 (27.6-34.2) 30.95 (28-34.35) 0.6618 31.75 (29.2-35.7) 31.5 (28.2-35.1) 0.6281 
Large HDL particle 
concentration (nmol/l) 
3.85 (2.9-5.3) 4.45 (3.35-5.7) 0.0261 5.75 (4.3-7.25) 6 (4.9-8.1) 0.2522 
Medium HDL particle 
concentration (nmol/l) 
9.2 (5.95-12.75) 9.95 (7.7-12.95) 0.256 10.65 (7.8-14.25) 10.55 (7.15-14.45) 0.9717 
Small HDL particle 
concentration (nmol/l)) 
17.2 (13.65-20.25) 16.05 (13.3-18.7) 0.1343 15.1 (11.70-17.75) 13.80 (11.25-16.15) 0.0642 
Mean HDL particle size (nm) 9.15 (8.85-9.5) 9.3 (9-9.6) 0.1055 9.6 (9.2-9.9) 9.7 (9.4-10) 0.0854 
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Version 3 Men Women 
 
CAD 
(n=75) 
NO CAD 
(n=185) 
p-value 
CAD 
(n=64) 
NO CAD 
(n=198) 
p-value 
Total VLDL and chylomicron 
particle concentration (nmol/l) 
46.5 (35.35-67.3) 36.95 (27.85-47.05) <.0001 42.5 (30.7-54.7) 32.95 (25.35-46.5) 0.011 
Large VLDL and chylomicron 
particle concentration (nmol/l) 
2.45 (1.4-3.75) 1.6 (0.9-2.7) 0.0002 1.75 (0.8-2.75) 1.3 (0.7-2.15) 0.0419 
Medium VLDL and chylomicron 
particle concentration (nmol/l) 
9.45 (4.9-15.15) 7.45 (4.3-11.35) 0.0404 8.85 (5.85-14.7) 7.4 (4.55-11.05) 0.0339 
Small VLDL and chylomicron 
particle concentration (nmol/l) 
37.2 (24.6-50.15) 27.05 (19.4-35.65) <.0001 30.6 (19.85-42.6) 25.95 (17.3-36.05) 0.05 
Mean VLDL particle size (nm) 46.35 (44.45-48.65) 46.4 (43.1-49.5) 0.9812 45.6 (43.2-49.7) 45.7 (42.7-48.9) 0.89 
              
Total LDL concentration 
(nmol/l) 
975.5 (845.5-1239.5) 813.5 (647.5-987) <.0001 914 (755.5-1131) 759 (643.5-959.5) 0.0005 
Large LDL concentration 
(nmol/l) 
192.5 (95-317) 214 (102-351) 0.495 289.5 (170.5-467.5) 314.5 (177-463.5) 0.93 
Small LDL concentration 
(nmol/l) 
587.5 (404.5-791) 405 (184.5-540) <.0001 342 (51-610) 105 (43-444.5) 0.046 
Mean LDL particle size (nm) 20.6 (20.2-21.1) 20.9 (20.4-21.3) 0.0063 21.05 (20.6-21.5) 21.2 (20.8-21.6) 0.1649 
       
IDL concentration (nmol/l) 215 (143-290.5) 189 (108.5-273) 0.0497 277.5 (173-370) 217.5 (145-295.5) 0.006 
       
NMR calculated total 
triglycerides (mg/dL) 
95 (79-123.5) 79 (67-96) <.0001 88.5 (76-112) 77 (65.5-95) 0.0005 
NMR calculated VLDL and 
chylomicron triglyceride 
(mg/dL) 
61.7 (43.55-83.65) 46.45 (35.95-61.95) <.0001 52.9 (36.1-71.95) 41.65 (33.6-59.15) 0.0167 
NMR calculated total HDL 
cholesterol (mg/dL) 
42.5 (37-47) 45 (40-49.5) 0.042 48.5 (42-56) 49 (44.5-56.5) 0.2981 
              
HDL cholesterol (enzymatic) 46.5 (40.2-56.4) 49.4 (44-56.5) 0.0201 57 (47.5-63.8) 56.45 (50.2-66.8) 0.5203 
  
1
9
 
Version 3 Men Women 
 
CAD 
(n=75) 
NO CAD 
(n=185) 
p-value 
CAD 
(n=64) 
NO CAD 
(n=198) 
p-value 
LDL cholesterol (enzymatic) 125.7 (110.3-150.85) 102.6 (86.4-126.4) <.0001 118 (103.1-144.4) 102.5 (89.7-123.4) 0.0015 
Total cholesterol (enzymatic) 203 (177-230) 168 (153-195) <.0001 192 (177-225) 178.5 (162-206) 0.0009 
Non-HDL 
cholesterol(enzymatic) 
149 (131.5-182.9) 117.15 (101.3-145.9) <.0001 138.5 (122.5-168) 119.6 (100.7-142.6) 0.0003 
      
 
      
Glomerular filtration Cockcroft-
Gault 
110.78 (78.16-138.45) 119.32 (102.29-143.91) 0.0118 94.92 (79.17-123.96) 112.84 (87.64-141.93) 0.0148 
Glomerular filtration MDRD  84.72(61.98-108.03) 100.73 (82.353-125.743) <.0001 84.96 (68.836-109.726) 96.52 (76.10-124.31) 0.0219 
Glomerular filtration CDK-Epi 96.64 (69.51-116.89) 111.66 (93.57-127.37) <.0001 99.81 (79.14-118.71) 111.83 (88.67-128.82) 0.004 
Duration of diabetes 24.9 (18.22-30) 16.64 (11.42-21.55) <.0001 25.37 (19.775-31.05) 16.93 (12.37-21.96) <.0001 
PULSE 80 (72-84) 76 (68-80) 0.037 80 (72-88) 78 (70-84) 0.0829 
AGE 31.69 (26.44-37.56) 24.63 (20.73-29.8) <.0001 33.46 (28.47-38.70) 25.24 (20.76-31.06) <.0001 
Body mass index 24.56 (22.99-26.46) 23.25 (21.37-25.24) 0.0022 22.75 (20.88-26.63) 22.815 (21.38-25.29) 0.787 
Albumin excretion rate 53.66 (9.94-592.08) 11.26 (6.83-36.86) <.0001 18.72 (7.73-235.28) 10.44 (6.22-33.24) 0.0512 
Waist to hip ratio 0.88 (0.84-0.92) 0.86 (0.83-0.89) 0.0014 0.785 (0.74-0.82) 0.76 (0.73-0.8) 0.0489 
Systolic blood pressure 119 (110-135) 111 (105-117) <.0001 111 (100-123) 106 (99-113) 0.0103 
Diastolic blood pressure 80 (73-85) 73 (67-79) <.0001 68 (62-76) 68 (64-73) 0.5566 
Fibrinogen 300 (220-370) 250 (205-300) 0.0011 300 (250-375) 280 (240-340) 0.2247 
White blood cell count 6.4 (5.5-7.7) 5.8 (5.1-7) 0.0098 6.9 (5.8-8.5) 6.2 (5.3-7.6) 0.0083 
Insulin dose per body weight 0.72 (0.61-0.86) 0.822 (0.66-0.94) 0.0283 0.68 (0.53-0.85) 0.775 (0.60-0.93) 0.0271 
HbA1c 8.772 (7.942-9.851) 8.44 (7.69-9.77) 0.154 8.77 (7.69-10.27) 8.52 (7.69-9.60) 0.1135 
Estimated glucose disposal rate 7.03 (5.21-7.66) 7.88 (6.63-8.69) <.0001 8.1 (6.58-9.28) 9.05 (7.79-9.9) 0.0004 
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Four separate Cox proportional hazards models were run to assess the predictive 
ability of lipoprotein subfractions by the two NMR versions for CAD incidence. The first 
Cox proportional hazards model allowed for traditional CAD risk factors and univariately 
significant variables, including Duration of diabetes, Sex, Waist to hip ratio, Having ever 
smoked, HbA1c, Insulin dose per body weight, Hypertension, Pulse, Albumin excretion 
rate, Glomerular filtration rate by the CKD-Epi formula, Fibrinogen, and White blood 
cell count, in addition to enzymatically measured HDL cholesterol and Non-HDL 
cholesterol; results as expected were identical for both versions. Specifically, duration of 
diabetes, having ever smoked, enzymatic Non-HDL cholesterol and Time dependent 
HbA1c were directly related to the incidence of CAD, while enzymatic HDL cholesterol 
and Glomerular filtration rate by the CKD-Epi formula were inversely related to CAD. 
The second model allowed for the same variables as in Model 1, but replaced 
enzymatically measured lipid concentrations with HDL subfractions measured by NMR; 
results from these models were still very similar for the two NMR versions. Thus, large 
HDL particle concentration by either NMR version was chosen as an independent 
predictor, and was inversely related to the incidence of CAD. Small and medium HDL 
particle concentrations were not selected as independent predictors in either NMR 
version. The third model was constructed as Model 1 but replaced enzymatically 
measured lipid concentrations with NMR measured HDL size. HDL size as measured by 
either version of NMR, however, was not selected as a significant CAD predictor.  The 
fourth model considered both enzymatically measured lipids and HDL subfractions by 
NMR simultaneously. Large HDL particle concentration by NMR and Non-HDL 
cholesterol were selected regardless NMR version. Large HDL particle concentration was 
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inversely related and time dependent Non-HDL cholesterol directly related to incident 
CAD. Differences in the predictive ability of HDL lipoprotein subfractions in relation to 
CAD incidence between the two NMR versions were, therefore, not observed from these 
Cox proportional hazards models. 
  
   
2
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Table 3 Cox Proportional Hazards models 
NMR Version 1   NMR Version 3 
           Model1:HDL cholesterol (enzymatic), Non-HDL cholesterol (enzymatic), Duration of diabetes, Sex, Waist to hip ratio, Having ever smoked, HbA1c, Insulin dose per body weight, Hypertension, Pulse, 
Albumin excretion rate, Glomerular filtration rate by CDK-Epi formula, Fibrinogen, White blood cell count / Sex *  HDL cholesterol (enzymatic) 
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio  
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard Ratio 
Duration of diabetes <.0001 1.113 1.08 1.14 
 
Duration of diabetes <.0001 1.111 1.08 1.141 
Having ever smoked 0.0357 1.494 1.03 2.17 
 
Having ever smoked 0.0369 1.493 1.03 2.175 
HDL cholesterol (enzymatic) 0.0049 0.977 0.96 0.99 
 
HDL cholesterol (enzymatic) 0.0058 0.978 0.96 0.994 
Non-HDL cholesterol (enzymatic) 0.0065 1.007 1 1.01 
 
Non-HDL cholesterol (enzymatic) 0.0035 1.007 1 1.012 
CKDEpi 0.0038 0.991 0.99 1 
 
CKDEpi 0.002 0.991 0.99 0.997 
Time dependent HbA1c 0.0352 1.066 1 1.13 
 
Time dependent HbA1c 0.0301 1.068 1.01 1.134 
          
 
          
Model2:  Large HDL particle concentration, Medium HDL particle concentration, Small HDL particle concentration, Duration of diabetes, Sex, Waist to hip ratio, Having ever smoked, HbA1c, Insulin 
dose per body weight, Hypertension, Pulse, Albumin excretion rate, Glomerular filtration rate by CDK-Epi formula, Fibrinogen, White blood cell count / Sex *  (Large HDL particle concentration, 
Medium HDL particle concentration, Small HDL particle concentration) 
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio  
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard Ratio 
Duration of diabetes <.0001 1.107 1.08 1.14 
 
Duration of diabetes <.0001 1.112 1.08 1.141 
Time dependent HbA1c 0.0038 1.091 1.03 1.16 
 
Time dependent HbA1c 0.0027 1.094 1.03 1.161 
Hypertension 0.075 1.587 0.96 2.64 
 
PULSE 0.0768 1.017 1 1.036 
Albumin excretion rate 0.0245 1 1 1 
 
Albumin excretion rate 0.0045 1 1 1 
CKDEpi 0.0896 0.994 0.99 1 
 
CKDEpi 0.0092 0.992 0.99 0.998 
Large HDL particle concentration 0.0032 0.898 0.84 0.97 
 
Large HDL particle concentration 0.0264 0.908 0.83 0.989 
 
        
  
        
Model 3:Mean HDL particle size,  Duration of diabetes, Sex, Waist to hip ratio, Having ever smoked, HbA1c, Insulin dose per body weight, Hypertension, Pulse, Albumin excretion rate, Glomerular 
filtration rate by CDK-Epi formula, Fibrinogen, White blood cell count / Sex *  Mean HDL particle size 
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio  
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard Ratio 
Duration of diabetes <.0001 1.111 1.08 1.14 
 
Duration of diabetes <.0001 1.106 1.08 1.136 
Time dependent HbA1c 0.0058 1.087 1.03 1.15 
 
Time dependent HbA1c 0.0011 1.101 1.04 1.166 
Albumin excretion rate 0.0019 1 1 1 
 
Albumin excretion rate 0.0012 1 1 1 
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Hypertension 0.0253 1.719 1.07 2.76 
 
Waist to hip ratio 0.0268 17.017 1.39 208.96 
White blood cell count 0.0182 1.105 1.02 1.2 
 
CKDEpi 0.0035 0.99 0.98 0.997 
 
        
 
          
Model 4: HDL cholesterol (enzymatic), Non-HDL cholesterol (enzymatic), Large HDL particle concentration, Medium HDL particle concentration, Small HDL particle concentration, Duration of diabetes, 
Sex, Waist to hip ratio, Having ever smoked, HbA1c, Insulin dose per body weight, Hypertension, Pulse, Albumin excretion rate, Glomerular filtration rate by CDK-Epi formula, Fibrinogen, White blood 
cell count / Sex * ( HDL cholesterol (enzymatic), Non-HDL cholesterol (enzymatic), Large HDL particle concentration, Medium HDL particle concentration, Small HDL particle concentration) 
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard 
Ratio  
Parameter Pr > ChiSq 
Hazard 
Ratio 
95% Hazard Ratio 
Duration of diabetes <.0001 1.104 1.08 1.14 
 
Duration of diabetes <.0001 1.109 1.08 1.139 
Having ever smoked 0.0863 1.392 0.95 2.03 
 
Having ever smoked 0.0808 1.404 0.96 2.055 
Time dependent HbA1c 0.0367 1.069 1 1.14 
 
Time dependent HbA1c 0.0274 1.072 1.01 1.14 
Time dependent Non-HDL 
cholesterol (enzymatic) 
0.0424 1.002 1 1.01 
 
Time dependent Non-HDL 
cholesterol (enzymatic) 
0.0054 1.003 1 1.005 
CKDEpi 0.0571 0.993 0.99 1 
 
CKDEpi 0.0028 0.99 0.98 0.997 
Large HDL particle concentration 0.0032 0.897 0.83 0.96 
 
Large HDL particle concentration 0.0135 0.897 0.82 0.978 
Hypertension 0.0488 1.649 1 2.71 
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Discussion  
As has been previously shown in multiple, independent research studies, 
individuals with type 1 diabetes are at increased risk for coronary heart disease compared 
to the general population9, despite generally normal lipid concentrations.  
While it is widely accepted that low density lipoprotein cholesterol is a major risk 
factor for the development of CAD, the role of high density lipoprotein cholesterol 
remains uncertain. Although it was believed earlier that higher HDL concentrations 
indicates lower CAD risk, more recent studies have noted the presence of a direct 
association with the development of CAD10, 11, 12. Thus suggestions were raised that HDL 
may be dysfunctional in type 1 diabetes13, and, further, that the concentration of HDL 
alone may not be an adequate measure of CAD risk in the type 1 diabetes population 
subgroup.  It was thus suggested that measures of HDL function and/or HDL subfractions 
may provide a better assessment of CAD risk. One method of determining the 
concentrations of very low density lipoprotein, low density lipoprotein, and high density 
lipoprotein subclasses of different size is through nuclear magnetic resonance 
spectroscopy (NMR). 
Nuclear magnetic resonance can differentiate lipoprotein subclasses based on 
small differences in the spectral properties of the lipids carried within the particles14, 15. 
An earlier version of this NMR technique, developed by Dr. James Otvos, was used to 
measure lipoprotein subfractions in a coronary artery disease case control study in the 
early 2000s. This case-control study was nested within the Epidemiology of Diabetes 
Complications study and comprised 142 study participants8. The study showed that 
higher large HDL particle concentrations by NMR indicated lower CAD risk, whereas 
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higher medium HDL particle concentration by NMR indicated higher CAD risk. Since 
that time period, however, a newer version of NMR has been developed. We, thus, aimed 
to evaluate whether our prediction of CAD risk could improve with the newer NMR 
version in this population. Plasma samples from 522 participants of the Epidemiology of 
Diabetes Complications study were available to assess lipoprotein subclasses by the 
earlier and more recent NMR version (version 1 and version 3). We analyzed the data and 
our findings indicated no substantial difference between the two versions of NMR in the 
prediction of CAD incidence with HDL lipoprotein subfractions as the main independent 
variables. Our analysis also further confirmed the inverse association between larger 
HDL particle concentration by NMR and CAD incidence in type 1 diabetes, which was 
consistent between NMR versions. However, contrary to the previously published case-
control study, in this analysis Medium HDL particle concentration did not differ by CAD 
incidence in the overall cohort, as well as in analysis stratifying the cohort by gender. 
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Conclusion  
In our EDC study, a difference in the ability to predict CAD incidence was not 
identified between the two distinct methods of classifying HDL lipoprotein subfractions 
by NMR, i.e. version 1 (2000) and version 3(2010). Analysis using either version further 
confirmed that large HDL particle concentration by NMR contributes to the prediction of 
CAD incidence in this type 1 diabetes cohort, beyond enzymatic measurements. 
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Appendix 
Table 4. Correlations between the NMR version 1 and all other continuous variables (Overall n=522) 
  Total HDL  Large HDL  Medium HDL  Small HDL  HDL size  (H3) HDL  (H4+H5) HDL  (H1+H2) HDL  
NTG 0.376 <.0001 -0.235 <.0001 0.308 <.0001 0.233 <.0001 -0.298 <.0001 0.308 <.0001 -0.230 <.0001 0.245 <.0001 
NTC 0.502 <.0001 0.117 0.008 0.158 0.000 0.226 <.0001 0.005 0.911 0.158 0.000 0.119 0.007 0.261 <.0001 
NVTG 0.292 <.0001 -0.340 <.0001 0.316 <.0001 0.222 <.0001 -0.377 <.0001 0.316 <.0001 -0.334 <.0001 0.225 <.0001 
NLC 0.330 <.0001 -0.158 0.000 0.155 0.000 0.234 <.0001 -0.232 <.0001 0.155 0.000 -0.165 0.000 0.241 <.0001 
NHC 0.499 <.0001 0.853 <.0001 0.002 0.965 -0.050 0.260 0.725 <.0001 0.002 0.965 0.873 <.0001 0.017 0.701 
CKDEpi -0.069 0.117 0.103 0.019 0.076 0.087 -0.159 0.000 0.020 0.659 0.076 0.087 0.065 0.140 -0.146 0.001 
MDRD -0.068 0.126 0.084 0.058 0.069 0.120 -0.143 0.001 -0.001 0.983 0.069 0.120 0.045 0.309 -0.130 0.003 
gfrcg -0.046 0.298 -0.021 0.642 0.090 0.041 -0.072 0.103 -0.113 0.011 0.090 0.041 -0.064 0.146 -0.070 0.114 
CHOL 0.346 <.0001 -0.090 0.043 0.190 <.0001 0.162 0.000 -0.080 0.074 0.190 <.0001 -0.056 0.208 0.166 0.000 
HDL 0.324 <.0001 0.768 <.0001 -0.083 0.060 -0.090 0.040 0.682 <.0001 -0.083 0.060 0.784 <.0001 -0.060 0.177 
LDL 0.214 <.0001 -0.301 <.0001 0.132 0.004 0.227 <.0001 -0.247 <.0001 0.132 0.004 -0.269 <.0001 0.212 <.0001 
nonhdl 0.225 <.0001 -0.356 <.0001 0.233 <.0001 0.192 <.0001 -0.318 <.0001 0.233 <.0001 -0.329 <.0001 0.181 <.0001 
fHDL3 0.374 <.0001 0.287 <.0001 0.143 0.001 0.067 0.130 0.164 0.000 0.143 0.001 0.271 <.0001 0.073 0.100 
fHDL2 0.099 0.028 0.702 <.0001 -0.213 <.0001 -0.141 0.002 0.715 <.0001 -0.213 <.0001 0.741 <.0001 -0.113 0.012 
AER 0.107 0.015 -0.211 <.0001 0.006 0.886 0.223 <.0001 -0.167 0.000 0.006 0.886 -0.191 <.0001 0.193 <.0001 
BMI 0.029 0.516 -0.222 <.0001 0.072 0.104 0.096 0.030 -0.231 <.0001 0.072 0.104 -0.235 <.0001 0.076 0.086 
DBP 0.094 0.033 -0.241 <.0001 0.084 0.057 0.147 0.001 -0.243 <.0001 0.084 0.057 -0.242 <.0001 0.117 0.008 
SBP 0.162 0.000 -0.261 <.0001 0.056 0.208 0.238 <.0001 -0.240 <.0001 0.056 0.208 -0.246 <.0001 0.220 <.0001 
FIB 0.047 0.284 -0.155 0.000 0.188 <.0001 -0.004 0.930 -0.096 0.030 0.188 <.0001 -0.129 0.003 -0.002 0.964 
WBC -0.050 0.261 -0.230 <.0001 0.079 0.073 -0.001 0.975 -0.166 0.000 0.079 0.073 -0.216 <.0001 -0.017 0.706 
GDR -0.130 0.003 0.379 <.0001 -0.146 0.001 -0.210 <.0001 0.394 <.0001 -0.146 0.001 0.386 <.0001 -0.171 0.000 
ghb 0.116 0.008 -0.118 0.008 0.156 0.000 0.061 0.171 -0.167 0.000 0.156 0.000 -0.132 0.003 0.056 0.205 
inswt -0.106 0.019 -0.160 0.000 0.132 0.004 -0.101 0.026 -0.177 <.0001 0.132 0.004 -0.183 <.0001 -0.101 0.027 
screa 0.051 0.252 -0.229 <.0001 -0.055 0.217 0.213 <.0001 -0.165 0.000 -0.055 0.217 -0.203 <.0001 0.181 <.0001 
whr 0.056 0.224 -0.473 <.0001 0.079 0.088 0.229 <.0001 -0.479 <.0001 0.079 0.088 -0.486 <.0001 0.192 <.0001 
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age 0.121 0.006 -0.039 0.372 -0.150 0.001 0.203 <.0001 0.020 0.650 -0.150 0.001 -0.002 0.966 0.215 <.0001 
DUR 0.111 0.011 -0.072 0.104 -0.102 0.020 0.173 <.0001 -0.020 0.643 -0.102 0.020 -0.042 0.336 0.183 <.0001 
PULSE 0.061 0.169 -0.053 0.228 0.080 0.068 -0.005 0.919 -0.066 0.133 0.080 0.068 -0.062 0.162 0.004 0.928 
CHY -0.018 0.681 0.159 0.000 -0.002 0.955 -0.114 0.010 0.146 0.001 -0.002 0.955 0.156 0.000 -0.106 0.016 
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Table 5. Correlations between the NMR version 3 and all other continuous variables (Overall n=522) 
  HDLP3   HLP3   HMP3   HSP3   HZ3   
NTG3 0.37208 <.0001 -0.18129 <.0001 0.34107 <.0001 0.12594 0.0041 -0.17635 <.0001 
NVCTG3 0.28103 <.0001 -0.27617 <.0001 0.30243 <.0001 0.116 0.0083 -0.226 <.0001 
NHC3 0.63428 <.0001 0.81857 <.0001 0.32013 <.0001 -0.05651 0.1996 0.58347 <.0001 
fHDL3 0.39573 <.0001 0.27825 <.0001 0.24183 <.0001 0.0422 0.3397 0.16935 0.0001 
fHDL2 0.11916 0.0078 0.70186 <.0001 0.02447 0.586 -0.24274 <.0001 0.61375 <.0001 
DUR 0.03859 0.3812 -0.03669 0.4052 -0.09836 0.0253 0.12286 0.0052 -0.03309 0.4528 
PULSE 0.08262 0.061 -0.02744 0.5344 0.06694 0.1293 0.01265 0.7745 -0.00147 0.9734 
CADFUT -0.02819 0.5224 0.10439 0.0176 -0.02429 0.5815 -0.0533 0.2263 0.08197 0.0625 
age 0.03043 0.4899 0.01576 0.7208 -0.12346 0.0049 0.12695 0.0038 0.01383 0.7537 
bmi -0.00414 0.9255 -0.23689 <.0001 0.00455 0.9181 0.10121 0.0217 -0.21 <.0001 
aer 0.00499 0.9102 -0.15933 0.0003 -0.01109 0.8021 0.1272 0.0039 -0.12955 0.0033 
gfrcg 0.01718 0.6971 -0.07597 0.0847 0.03822 0.3863 0.03534 0.4231 -0.1169 0.0079 
MDRD 0.01721 0.6965 0.0355 0.421 0.04657 0.2911 -0.03343 0.4486 -0.01346 0.7603 
whr -0.02074 0.6552 -0.48228 <.0001 -0.02476 0.5939 0.24663 <.0001 -0.4384 <.0001 
sbp 0.08363 0.0577 -0.21739 <.0001 0.00171 0.969 0.19781 <.0001 -0.20052 <.0001 
dbp 0.03741 0.3965 -0.20924 <.0001 0.02682 0.5433 0.11906 0.0068 -0.18053 <.0001 
hdl 0.35706 <.0001 0.76581 <.0001 0.17616 <.0001 -0.16752 0.0001 0.63085 <.0001 
ldl 0.14458 0.0014 -0.22687 <.0001 0.10568 0.0197 0.13708 0.0024 -0.18008 <.0001 
chol 0.3326 <.0001 0.00346 0.938 0.24812 <.0001 0.06085 0.1709 0.02642 0.5525 
nonhdl 0.19655 <.0001 -0.27023 <.0001 0.19726 <.0001 0.11569 0.0091 -0.20634 <.0001 
fib 0.07444 0.0918 -0.08895 0.0438 0.13602 0.002 -0.01995 0.6519 -0.02057 0.6418 
wbc -0.06453 0.1456 -0.18953 <.0001 0.02329 0.5998 -0.04348 0.3271 -0.06395 0.1493 
inswt -0.0609 0.1788 -0.18395 <.0001 0.0709 0.1174 -0.04122 0.363 -0.12642 0.0051 
ghb 0.12856 0.0035 -0.1151 0.0089 0.12133 0.0058 0.10069 0.0223 -0.14345 0.0011 
CKDEpi 0.02088 0.6361 0.05586 0.2053 0.05969 0.1758 -0.05118 0.2459 0.00845 0.8481 
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gdr -0.05603 0.2057 0.35585 <.0001 -0.05949 0.179 -0.19341 <.0001 0.33466 <.0001 
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Table 6 Correlations between the NMR version 3 and all other continuous variables (Non-CAD group n=383) 
 
HDLP3 
 
HLP3 
 
HMP3 
 
HSP3 
 
HZ3 
 NTG3 0.435 <.0001 -0.144 0.005 0.383 <.0001 0.101 0.050 -0.144 0.005 
NVCTG3 0.338 <.0001 -0.262 <.0001 0.336 <.0001 0.112 0.028 -0.220 <.0001 
NHC3 0.599 <.0001 0.811 <.0001 0.281 <.0001 -0.080 0.118 0.602 <.0001 
fHDL3 0.379 <.0001 0.233 <.0001 0.238 <.0001 0.060 0.246 0.124 0.016 
fHDL2 0.095 0.069 0.723 <.0001 0.006 0.915 -0.276 <.0001 0.651 <.0001 
DUR 0.081 0.113 0.006 0.900 -0.046 0.371 0.090 0.079 0.008 0.870 
PULSE 0.102 0.048 -0.004 0.941 0.109 0.034 -0.030 0.563 0.020 0.693 
age 0.047 0.361 0.047 0.365 -0.087 0.091 0.087 0.090 0.044 0.388 
bmi 0.014 0.786 -0.225 <.0001 -0.012 0.823 0.117 0.023 -0.193 0.000 
aer 0.057 0.268 -0.093 0.070 0.046 0.374 0.091 0.076 -0.079 0.126 
gfrcg 0.017 0.734 -0.083 0.107 0.005 0.925 0.059 0.251 -0.125 0.015 
MDRD 0.028 0.590 0.014 0.786 0.042 0.414 -0.014 0.780 -0.045 0.384 
CKDEpi 0.024 0.641 0.031 0.541 0.045 0.381 -0.029 0.572 -0.024 0.639 
whr -0.001 0.992 -0.479 <.0001 -0.004 0.934 0.239 <.0001 -0.450 <.0001 
sbp 0.081 0.115 -0.183 0.000 0.027 0.597 0.162 0.002 -0.151 0.003 
dbp 0.049 0.342 -0.168 0.001 0.054 0.292 0.077 0.133 -0.124 0.016 
hdl 0.315 <.0001 0.771 <.0001 0.138 0.007 -0.178 0.001 0.644 <.0001 
ldl 0.190 0.000 -0.173 0.001 0.175 0.001 0.079 0.136 -0.136 0.010 
chol 0.375 <.0001 0.066 0.207 0.308 <.0001 -0.017 0.745 0.088 0.091 
nonhdl 0.247 <.0001 -0.226 <.0001 0.266 <.0001 0.055 0.291 -0.165 0.001 
fib 0.118 0.022 -0.076 0.138 0.159 0.002 -0.015 0.778 -0.020 0.703 
wbc -0.008 0.876 -0.159 0.002 0.056 0.284 -0.043 0.403 -0.037 0.477 
inswt -0.016 0.760 -0.203 0.000 0.083 0.119 0.012 0.819 -0.154 0.004 
ghb 0.129 0.012 -0.133 0.010 0.151 0.003 0.071 0.167 -0.160 0.002 
gdr -0.082 0.112 0.366 <.0001 -0.074 0.150 -0.200 <.0001 0.360 <.0001 
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Table 7 Correlations between the NMR version 3 and all other continuous variables (CAD group n=139) 
  HDLP3   HLP3   HMP3   HSP3   HZ3   
NTG3 0.272 0.001 -0.153 0.075 0.290 0.001 0.154 0.073 -0.145 0.090 
NVCTG3 0.180 0.036 -0.219 0.010 0.260 0.002 0.105 0.221 -0.161 0.061 
NHC3 0.735 <.0001 0.815 <.0001 0.417 <.0001 0.042 0.627 0.508 <.0001 
fHDL3 0.443 <.0001 0.326 0.000 0.239 0.005 0.049 0.569 0.210 0.014 
fHDL2 0.172 0.049 0.640 <.0001 0.056 0.523 -0.127 0.148 0.498 <.0001 
DUR -0.053 0.541 -0.001 0.992 -0.195 0.023 0.098 0.253 0.000 0.996 
PULSE 0.029 0.734 -0.054 0.530 -0.020 0.820 0.089 0.303 -0.023 0.788 
age 0.013 0.877 0.123 0.154 -0.197 0.021 0.134 0.120 0.090 0.295 
bmi -0.058 0.508 -0.221 0.010 0.060 0.490 0.021 0.806 -0.209 0.015 
aer -0.128 0.139 -0.236 0.006 -0.131 0.129 0.181 0.036 -0.180 0.036 
gfrcg 0.020 0.814 -0.105 0.223 0.115 0.181 -0.005 0.951 -0.134 0.120 
MDRD 0.005 0.951 0.007 0.940 0.063 0.468 -0.054 0.531 -0.009 0.921 
CKDEpi 0.028 0.749 0.026 0.768 0.097 0.263 -0.071 0.410 0.011 0.902 
whr -0.066 0.483 -0.434 <.0001 -0.066 0.481 0.217 0.019 -0.361 <.0001 
sbp 0.081 0.347 -0.231 0.007 -0.035 0.685 0.237 0.005 -0.241 0.005 
dbp 0.016 0.851 -0.242 0.005 -0.012 0.894 0.176 0.040 -0.247 0.004 
hdl 0.455 <.0001 0.734 <.0001 0.268 0.002 -0.107 0.214 0.570 <.0001 
ldl 0.023 0.799 -0.266 0.002 -0.046 0.605 0.199 0.023 -0.187 0.033 
chol 0.270 0.002 0.015 0.859 0.156 0.070 0.168 0.052 0.026 0.765 
nonhdl 0.080 0.356 -0.271 0.002 0.058 0.504 0.185 0.032 -0.192 0.026 
fib -0.035 0.683 -0.062 0.471 0.107 0.214 -0.074 0.389 0.027 0.752 
wbc -0.219 0.010 -0.202 0.018 -0.047 0.588 -0.108 0.211 -0.045 0.602 
inswt -0.165 0.058 -0.203 0.019 0.016 0.856 -0.104 0.235 -0.123 0.158 
ghb 0.125 0.146 -0.025 0.770 0.067 0.439 0.133 0.121 -0.062 0.474 
gdr 0.034 0.696 0.258 0.002 -0.042 0.626 -0.117 0.175 0.206 0.016 
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Table 8 Correlations between the NMR version 3 and all other continuous variables (Men group n=260) 
  HDLP3   HLP3   HMP3   HSP3   HZ3   
NTG3 0.319 <.0001 -0.169 0.007 0.202 0.001 0.183 0.003 -0.150 0.016 
NVCTG3 0.265 <.0001 -0.216 0.001 0.181 0.004 0.159 0.011 -0.153 0.014 
NHC3 0.657 <.0001 0.792 <.0001 0.404 <.0001 0.024 0.703 0.518 <.0001 
fHDL3 0.270 <.0001 0.241 0.000 0.182 0.004 0.015 0.809 0.159 0.011 
fHDL2 0.084 0.189 0.533 <.0001 0.078 0.220 -0.202 0.001 0.394 <.0001 
DUR 0.034 0.590 -0.145 0.020 -0.132 0.034 0.173 0.005 -0.135 0.031 
PULSE 0.005 0.939 -0.079 0.207 0.016 0.805 0.039 0.536 -0.025 0.690 
age 0.031 0.618 -0.130 0.037 -0.116 0.063 0.166 0.008 -0.105 0.094 
bmi -0.027 0.672 -0.189 0.003 -0.085 0.175 0.110 0.080 -0.196 0.002 
aer -0.036 0.571 -0.151 0.016 -0.043 0.494 0.063 0.315 -0.067 0.284 
gfrcg 0.014 0.822 -0.014 0.821 0.027 0.669 0.041 0.515 -0.074 0.235 
MDRD 0.031 0.620 0.076 0.227 0.100 0.109 -0.034 0.593 0.012 0.853 
CKDEpi 0.028 0.650 0.091 0.146 0.100 0.111 -0.041 0.511 0.028 0.651 
whr -0.019 0.767 -0.286 <.0001 -0.051 0.435 0.167 0.011 -0.212 0.001 
sbp 0.075 0.228 -0.154 0.013 -0.022 0.729 0.143 0.022 -0.118 0.058 
dbp 0.047 0.449 -0.093 0.135 0.020 0.751 0.054 0.384 -0.030 0.630 
hdl 0.287 <.0001 0.673 <.0001 0.216 0.001 -0.169 0.007 0.518 <.0001 
ldl 0.130 0.043 -0.221 0.001 0.018 0.783 0.160 0.012 -0.143 0.025 
chol 0.243 <.0001 -0.048 0.449 0.115 0.068 0.125 0.047 0.016 0.801 
nonhdl 0.159 0.011 -0.239 0.000 0.066 0.297 0.170 0.007 -0.142 0.024 
fib 0.010 0.879 -0.110 0.080 0.084 0.182 -0.017 0.791 -0.029 0.639 
wbc -0.178 0.004 -0.189 0.002 -0.080 0.202 -0.050 0.426 -0.023 0.713 
inswt -0.061 0.351 -0.177 0.006 0.010 0.873 0.009 0.890 -0.156 0.016 
ghb 0.117 0.062 -0.099 0.112 0.151 0.015 0.041 0.509 -0.071 0.257 
gdr -0.070 0.263 0.195 0.002 -0.128 0.040 -0.050 0.424 0.103 0.099 
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Table 9 Correlations between the NMR version 3 and all other continuous variables (Women group n=262) 
  HDLP3   HLP3   HMP3   HSP3   HZ3   
NTG3 0.439 <.0001 -0.178 0.004 0.482 <.0001 0.022 0.725 -0.187 0.003 
NVCTG3 0.325 <.0001 -0.294 <.0001 0.441 <.0001 -0.004 0.944 -0.239 <.0001 
NHC3 0.624 <.0001 0.813 <.0001 0.223 0.000 0.010 0.870 0.543 <.0001 
fHDL3 0.505 <.0001 0.259 <.0001 0.274 <.0001 0.152 0.015 0.076 0.222 
fHDL2 0.121 0.056 0.741 <.0001 -0.089 0.158 -0.128 0.043 0.673 <.0001 
DUR 0.037 0.555 0.055 0.379 -0.078 0.207 0.119 0.055 0.040 0.516 
PULSE 0.148 0.017 -0.058 0.354 0.104 0.096 0.033 0.597 -0.079 0.203 
age 0.023 0.710 0.149 0.017 -0.143 0.021 0.147 0.017 0.108 0.082 
bmi 0.029 0.646 -0.265 <.0001 0.099 0.110 0.051 0.414 -0.210 0.001 
aer 0.054 0.388 -0.120 0.055 0.025 0.694 0.174 0.005 -0.167 0.007 
gfrcg 0.037 0.559 -0.062 0.323 0.075 0.227 -0.034 0.586 -0.089 0.155 
MDRD 0.011 0.858 0.048 0.441 0.016 0.793 -0.060 0.337 0.002 0.978 
CKDEpi 0.021 0.739 0.045 0.472 0.036 0.559 -0.069 0.267 -0.002 0.979 
whr 0.072 0.276 -0.350 <.0001 0.152 0.021 0.034 0.604 -0.256 <.0001 
sbp 0.130 0.037 -0.087 0.162 0.076 0.223 0.112 0.072 -0.067 0.282 
dbp 0.065 0.300 -0.110 0.077 0.101 0.106 0.008 0.901 -0.099 0.111 
hdl 0.413 <.0001 0.794 <.0001 0.094 0.133 -0.007 0.913 0.623 <.0001 
ldl 0.163 0.011 -0.234 0.000 0.188 0.003 0.092 0.154 -0.226 0.000 
chol 0.410 <.0001 0.015 0.813 0.353 <.0001 0.025 0.690 -0.014 0.825 
nonhdl 0.244 <.0001 -0.297 <.0001 0.328 <.0001 0.031 0.619 -0.274 <.0001 
fib 0.136 0.029 -0.234 0.000 0.167 0.007 0.080 0.204 -0.205 0.001 
wbc 0.023 0.712 -0.313 <.0001 0.097 0.122 0.040 0.521 -0.222 0.000 
inswt -0.049 0.445 -0.165 0.009 0.139 0.028 -0.138 0.030 -0.066 0.302 
ghb 0.146 0.019 -0.144 0.021 0.098 0.116 0.168 0.007 -0.250 <.0001 
gdr -0.121 0.053 0.299 <.0001 -0.104 0.097 -0.177 0.005 0.336 <.0001 
 
